Johnson & Johnson has plenty to say and even more information to share about the pending separation of its consumer health business despite regulatory limits on the firm’s discussion of it.
For instance, in the global pharmaceutical, medtech and consumer health product manufacturer and marketer’s 2022 fourth quarter, its “other income and expense” total of $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?